Neutralization of IL-17 by active vaccination inhibits IL-23-dependent autoimmune myocarditis

被引:146
作者
Sonderegger, Ivo
Roehn, Till A.
Kurrer, Michael O.
Iezzi, Giandomenica
Zou, Yu
Kastelein, Robert A.
Bachmann, Martin F.
Kopf, Manfred
机构
[1] ETH, Inst Integrat Biol Mol Biomed, CH-8952 Zurich, Switzerland
[2] Cytos Biotechnol AG, Zurich, Switzerland
[3] Univ Zurich, Dept Pathol, CH-8006 Zurich, Switzerland
[4] Schering Plough Biopharma, Discovery Res, Palo Alto, CA USA
关键词
autoimmunity; autovaccination; IL-17; IL-23; myocarditis;
D O I
10.1002/eji.200636484
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
The most common reason for heart failure in young adults is dilated cardiomyopathy often resulting from myocarditis. Clinical studies and animal models provide evidence that an autoimmune response against heart myosin is the underlying reason for the disease. IL-12 has been suggested to play a key role in development of experimental autoimmune myocarditis (EAM), as IL-12p40 and IL-12R beta 1 knockouts are protected from disease. In this study, we have compared IL-12p40(-/-) mice, IL-12p35(-/-) mice and mice treated with a neutralizing IL-23 antibody in EAM and found that in fact IL-23, not IL-12, is responsible for inflammatory heart disease. However, these cytokines appear to have redundant activity for priming and expansion of autoreactive CD4 T cells, as specific T cell proliferation was only defective in the absence of both cytokines. IL-23 has been suggested to promote a pathogenic IL-17-producing T cell population. We targeted IL-17 by capitalizing on an active vaccination approach that effectively breaks B cell tolerance. Neutralization of IL-17 reduced myocarditis and heart autoantibody responses, suggesting that IL-17 is the critical effector cytokine responsible for EAM. Thus, targeting of IL-23 and IL-17 by passive and active vaccination strategies holds promise as a therapeutic approach to treat patients at risk for development of dilated cardiomyopathy.
引用
收藏
页码:2849 / 2856
页数:8
相关论文
共 40 条
[1]   Interleukin-12 receptor/STAT4 signaling is required for the development of autoimmune myocarditis in mice by an interferon-γ-independent pathway [J].
Afanasyeva, M ;
Wang, Y ;
Kaya, Z ;
Stafford, EA ;
Dohmen, KM ;
Akha, AAS ;
Rose, NR .
CIRCULATION, 2001, 104 (25) :3145-3151
[2]   Interleukin-23 promotes a distinct CD4 T cell activation state characterized by the production of interleukin-17 [J].
Aggarwal, S ;
Ghilardi, N ;
Xie, MH ;
de Sauvage, FJ ;
Gurney, AL .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2003, 278 (03) :1910-1914
[3]   Low-molecular-weight tumor necrosis factor receptor p55 controls induction of autoimmune heart disease [J].
Bachmaier, K ;
Pummerer, C ;
Kozieradzki, I ;
Pfeffer, K ;
Mak, TW ;
Neu, N ;
Penninger, JM .
CIRCULATION, 1997, 95 (03) :655-661
[4]   Opinion - Therapeutic vaccination for chronic diseases: a new class of drugs in sight [J].
Bachmann, MF ;
Dyer, MR .
NATURE REVIEWS DRUG DISCOVERY, 2004, 3 (01) :81-88A
[5]   IL-12- and IL-23-induced T helper cell subsets: birds of the same feather flock together [J].
Bettelli, E ;
Kuchroo, VK .
JOURNAL OF EXPERIMENTAL MEDICINE, 2005, 201 (02) :169-171
[6]   Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells [J].
Bettelli, E ;
Carrier, YJ ;
Gao, WD ;
Korn, T ;
Strom, TB ;
Oukka, M ;
Weiner, HL ;
Kuchroo, VK .
NATURE, 2006, 441 (7090) :235-238
[7]  
Camoglio L, 2002, EUR J IMMUNOL, V32, P261, DOI 10.1002/1521-4141(200201)32:1<261::AID-IMMU261>3.0.CO
[8]  
2-X
[9]  
Camoglio L, 2000, EUR J IMMUNOL, V30, P1486, DOI 10.1002/(SICI)1521-4141(200005)30:5<1486::AID-IMMU1486>3.0.CO
[10]  
2-8